Drug profile · INN
plitidepsin
APLIDIN
plitidepsin (APLIDIN) is a elongation factor 1-alpha 2 inhibitor.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — plitidepsin
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
plitidepsin (APLIDIN) is a elongation factor 1-alpha 2 inhibitor.
Key facts
INN plitidepsin
Brand APLIDIN
Mechanism Elongation factor 1-alpha 2 inhibitor
Target Elongation factor 1-alpha 2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01
Mechanism of action
Elongation factor 1-alpha 2 inhibitor
Primary target: Elongation factor 1-alpha 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is plitidepsin?
plitidepsin (APLIDIN) is a elongation factor 1-alpha 2 inhibitor.
What is the brand name for plitidepsin?
APLIDIN is a marketed brand name for plitidepsin. Check FDA Drugs@FDA for the current US label holder and prescribing information.